EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate By Ogkologos - February 20, 2026 255 0 Facebook Twitter Google+ Pinterest WhatsApp New combination concerns a combination with ADT for the treatment of adult patients with mHSPC and BRCA1/2 mutations Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure... June 23, 2025 How to Cope With and Discuss an Uncertain Cancer Prognosis: An... September 7, 2023 Population-based lung cancer screening can reduce mortality in people who have... March 27, 2026 Heart Problems: Investigating the Cardiac Side Effects of Cancer Treatments September 21, 2018 Load more HOT NEWS Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients... News digest – HPV vaccine, 1 million breast screenings missed and... What’s at the Root of Ovarian Cancer? New Study May Have... FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell...
